(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 67.64% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.92%.
Ocular Therapeutix's revenue in 2026 is $52,038,000.On average, 14 Wall Street analysts forecast OCUL's revenue for 2026 to be $11,594,607,837, with the lowest OCUL revenue forecast at $9,741,984,248, and the highest OCUL revenue forecast at $12,953,037,898. On average, 14 Wall Street analysts forecast OCUL's revenue for 2027 to be $25,811,047,001, with the lowest OCUL revenue forecast at $12,038,002,562, and the highest OCUL revenue forecast at $63,224,803,373.
In 2028, OCUL is forecast to generate $58,462,415,586 in revenue, with the lowest revenue forecast at $22,938,287,104 and the highest revenue forecast at $113,574,737,695.